#None #New York #healthcare #CAR-T therapy #Leucid Bio

Leucid Bio's Participation at Morgan Stanley Annual Conference

Leucid Bio, a privately owned biotechnology firm, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The event is slated for September 8, 2025, in New York city, and is a significant opportunity for the company to showcase its advancements in innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies.

Event Details

Filippo Petti, the CEO of Leucid Bio, is set to engage in a fireside chat at 1:05 p.m. ET, where he will discuss the company's innovative approaches to CAR-T therapies utilizing their proprietary lateral CAR platform. Besides the fireside chat, Leucid's management team will hold one-on-one meetings with investors and key stakeholders during the conference, aiming for meaningful discussions around their groundbreaking treatments for solid tumors.

About Leucid Bio

Founded with a mission to develop transformative therapies for cancer treatment, Leucid Bio focuses on cell therapies specifically targeting solid tumors. The company's flagship product, LEU011, leverages a pioneering approach that involves using autologous CAR-T cells designed to target the NKG2D ligands. These ligands are present in over 80% of human tumors, suggesting a wide potential applicability of their therapy.

In addition to targeting tumor cells, LEU011 also incorporates the chemokine receptor CXCR2. This enhancement is strategically engineered to improve the trafficking and infiltration of therapeutic cells into tumors, improving the overall effectiveness of the treatment. The dual mechanism aims to create a more potent and efficient therapeutic response against solid tumors.

The Significance of the Conference

The Morgan Stanley Global Healthcare Conference is recognized as a premier platform for biotechnology and pharmaceutical companies to share their discoveries and innovations with a global audience. Leucid Bio's participation not only elevates its visibility among investors but also builds networks that are crucial for future growth and research collaborations.

In a field that is continuously evolving, where the demand for effective cancer therapies is paramount, Leucid Bio's innovative approaches and strategic participation in such high-profile events mark it as a key player in the biotechnology landscape.

For ongoing updates on Leucid Bio’s initiatives and further information about its products, interested parties are encouraged to visit Leucid Bio's official website.

Conclusion

Leucid Bio's innovative CAR-T therapies represent a promising advancement in cancer treatment, especially for patients with solid tumors. With a focused approach to leveraging its proprietary technology, Leucid Bio is positioned to make significant contributions to the field of oncology. The forthcoming conference will surely provide a critical platform for the company to engage with the healthcare community and share its vision for changing the future of cancer therapy.